Numerous studies have found autoantibodies against various molecules in AD patients, including autoantibodies against Aβ, tau, glial markers, vasculature-related molecules, cellular enzymes, and neurotransmitters and related receptors (Wu and Li, 2016). Here, MAPT is linked to Alzheimer disease.